Ratings for CVS Health (NYSE:CVS) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 4 | 1 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by a high estimate of $82.00 and a low estimate of $58.00. This current average has decreased by 0.93% from the previous average price target of $68.71.
A clear picture of CVS Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Macdonald | Truist Securities | Lowers | Buy | $60.00 | $67.00 |
| George Hill | Deutsche Bank | Maintains | Buy | $66.00 | $66.00 |
| Charles Ryhee | TD Cowen | Raises | Buy | $80.00 | $73.00 |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $64.00 | $72.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $67.00 | $76.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $66.00 | $60.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $58.00 | $68.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $62.00 | $60.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $71.00 | $75.00 |
| Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $60.00 | $61.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $66.00 | $73.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $75.00 | $82.00 |
| David Macdonald | Truist Securities | Raises | Buy | $76.00 | $66.00 |
| Andrew Mok | Barclays | Raises | Overweight | $82.00 | $63.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CVS Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on CVS Health analyst ratings.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CVS Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CVS Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CVS Health's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
January 9, 2025
·
Financial Times
Copyright © Traders & Quants
